Accueil   Diary - News   All news 1st patient randomized with Transgene Pexa-Vec

1st patient randomized with Transgene Pexa-Vec

Transgene S.A. today announced the initiation of a multinational, randomized Phase 3 open label study with the oncolytic  immunotherapy,
Pexa-Vec,  in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).


This trial is being led by Transgene’s partner, SillaJen, Inc.


The trial is evaluating the use of Pexa-Vec to treat HCC patients who are eligible for treatment with sorafenib (Nexavar®), the only approved drug for advanced HCC.


Read the press release